Peter Rehse joins BioFocus as Senior Director, Structural Biology
News Feb 11, 2013
His responsibilities will include managing the structural biology and fragment-based screening groups within the Biological Sciences division.
Peter joins BioFocus from the Chinese CRO Shanghai Medicilon Inc., where, as Vice President, he was responsible for the strategic business and scientific development of the structural biology and structure-based drug design unit. Prior to this Peter worked at RIKEN Harima Institute, in Japan and has held several academic positions in Japan and Canada. Peter studied for his PhD under the supervision of Professor Tom Blundell at the University of London and undertook post-doctoral research at the Max-Planck Institute.
“With Peter’s international credibility we will be able to strengthen and grow our structural biology and fragment screening operation,” commented Dr. Kate Hilyard, VP Biological Sciences, BioFocus. “This hire reflects our ongoing commitment to accelerate our client’s discovery programs through investing in the right people."
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE